InvestingPro subscribers have access to 13 additional key insights about Vertex's financial health and market position. The change in outlook comes after management indicated on the first-quarter results call that achieving broad unrestricted formulary access for Journavx remains a goal rather than a certainty. The firm has significantly lowered its sales forecasts for Journavx, citing a 56% reduction in the 2025 estimate from $144 million to $63 million, a 50% cut for 2026 from $721 million to $361 million, and a 39% decrease for the 2030 projection from $6.8 billion to $4.1 billion. These downward adjustments were partially balanced by increased projections for Vertex's cystic fibrosis (CF) franchise. Leerink Partners expressed that while Vertex holds promising long-term growth potential, the near-term performance of Journavx is challenging to predict. The firm also noted that they do not anticipate interim readouts for Vertex's other treatments, pove™ for IgA nephropathy and inaxaplin for AMKD, until 2026.